SCHEMBL21332937

SCHEMBL21332937

C#Cc1cc(C)c(=O)n(CC(=O)c2cnn(Cc3ccccc3)c2C)c1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
KMT2A Q03164 1/20 0.43
BRD4 O60885 2/20 0.41
TP53 P04637 4/20 0.40
MAPT P10636 2/20 0.40
TSHR P16473 2/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
RAB9A P51151 1/20 0.40
S1PR2 O95136 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PTGDR2 Q9Y5Y4 4/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.36
PFKFB3 Q16875 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21333176 0.90 KDM4E (0.44) KDM4ESMN1; SMN2KMT2ABRD4TP53
SCHEMBL21332669 0.88 KDM4E (0.43) KDM4ESMN1; SMN2KMT2ABRD4TP53
SCHEMBL21333548 0.86 S1PR2 (0.45) KDM4ESMN1; SMN2KMT2ATP53MAPT
SCHEMBL21333325 0.85 SMN1; SMN2 (0.45) KDM4ESMN1; SMN2KMT2ABRD4TP53
SCHEMBL22831429 0.83 KMT2A (0.41) KDM4ESMN1; SMN2KMT2ATSHRNPC1
SCHEMBL21332874 0.82 KMT2A (0.45) KDM4ESMN1; SMN2KMT2ABRD4TP53
SCHEMBL21333188 0.79 S1PR2 (0.43) KDM4ESMN1; SMN2KMT2ABRD4TP53
SCHEMBL21333082 0.79 KMT2A (0.40) KDM4ESMN1; SMN2KMT2AMAPTS1PR2
SCHEMBL21332677 0.79 KDM4E (0.42) KDM4ESMN1; SMN2KMT2ABRD4TP53
SCHEMBL30866462 0.79 KMT2A (0.40) KDM4ESMN1; SMN2KMT2AMAPTS1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3762377-B1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF UNIV CORNELL (US) 2025-08-20 EP disclosed
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof CORNELL UNIVERSITY (US) 2024-04-23 US disclosed
EP-3762377-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF Cook, Timothy, H. (US) 2021-01-13 EP disclosed
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE 2020-12-31 US disclosed
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE 2020-12-31 US disclosed
WO-2019173790-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF HLA TIMOTHY (US) 2019-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF PTGER1, LOXL1, COL1A1 KDM4E 2671/4885SMN1; SMN2 3979/4885KMT2A 4385/4885
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof PTGER1, LOXL1, COL1A1 KDM4E 2671/4885SMN1; SMN2 3979/4885KMT2A 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.